Sialylated Glycosylated Interferon Beta for Plasma Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing interferon β pharmaceuticals face challenges with reduced activity due to PEGylation, and glycosylation methods using CHO cells result in ununiform sugar chains, affecting drug efficacy and stability.
Innovation Solution
A glycosylated polypeptide with interferon β activity is developed, featuring sialylated sugar chains at specific positions, ensuring uniformity and stability, and synthesized using methods that avoid the limitations of PEGylation and CHO cell expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If PEGylation is used to improve physical stability, heat stability, and plasma stability of interferon β, then stability is improved, but pharmaceutical activity is reduced
Solution Approach 1:
The patent uses sialylated sugar chains as an intermediary substance to achieve stability enhancement without the harmful effects of PEGylation. The sugar chains are naturally occurring biocompatible molecules that can extend plasma half-life through recognized biological mechanisms (such as binding to lectins or avoiding renal clearance) while maintaining interferon β's pharmaceutical activity. This resolves the contradiction by finding a middle ground between stability enhancement and activity preservation.
2Reliability
If site-specific PEGylation with high molecular weight PEG is performed to maintain interferon β activity, then activity is maintained, but safety concerns arise due to in vivo accumulation
Solution Approach 1:
The patent changes the chemical parameter of the stabilizing molecule from synthetic PEG to naturally occurring sialylated sugar chains. This parameter change transforms the substance from potentially accumulative and unsafe to biocompatible and safely metabolizable. The sialylated sugar chains can be naturally degraded and eliminated through normal metabolic pathways, resolving the safety and accumulation concerns while maintaining the ability to enhance plasma half-life and preserve pharmaceutical activity.
3Productivity
If glycosylation is performed using CHO cell expression system to produce interferon β, then production is achieved, but sugar chain uniformity is poor
Solution Approach 1:
The patent extracts and isolates the glycosylation step from the cellular expression system. Instead of relying on CHO cells to perform glycosylation (which produces heterogeneous sugar chains), the invention uses chemically synthesized interferon β that is then glycosylated through controlled chemical reactions. This separation allows for precise control of sugar chain structure and uniformity while maintaining production capability, resolving the contradiction between productivity and manufacturing precision.
4Ease of manufacture
If amino acid mutations are introduced to create consensus sequence for N-linked sugar chain recognition, then glycosylation capability is improved, but additional amino acid mutations occur that may affect protein function
Solution Approach 1:
The patent performs glycosylation as a preliminary action after protein synthesis rather than relying on cellular machinery during expression. By synthesizing the interferon β protein first (without requiring consensus sequences or additional mutations) and then adding sugar chains through controlled chemical glycosylation, the invention avoids the need to introduce potentially harmful amino acid mutations. This preliminary glycosylation step ensures protein function is preserved while achieving the desired glycosylation capability.
Data Source
AI summary
The object of the present invention is to provide a polypeptide having interferon β activity glycosylated with highly uniform sialylated sugar chains. The present invention is a glycosylated polypeptide, wherein the polypeptide is any polypeptide selected from the group consisting of the following (1) to (4); (1) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, (2) a polypeptide having one or a few amino acids deleted, substituted, or added in the polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, (3) a polypeptide that is an analog of interferon β, and (4) a polypeptide having 80% or more homology to the polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, in which amino acids at 4 to 6 locations are substituted with glycosylated amino acids, and wherein all of the non-reducing terminals of said sugar chain are sialylated.